Skip to main content
Full access
Letters
Published Online: 1 July 2011

Amisulpride Augmentation of Clozapine in Refractory Schizophrenia

Publication: The Journal of Neuropsychiatry and Clinical Neurosciences
To the Editor: Clozapine, an atypical antipsychotic drug, is the first-choice medication for treatment-refractory schizophrenia. However, clozapine can cause some adverse effects, such as agranulocytosis and sialorrhea, making it difficult for patients to continue with treatment. Otherwise, treatment options for patients who are resistant to clozapine are extremely limited. Herein, the authors report the case of a patient with refractory schizophrenia treated by amisulpride augmentation of clozapine who got significant improvement not only in his positive and negative symptoms but also the side effect of salivation. This case report might provide an alternative treatment for refractory schizophrenia.

Case Report

A 53-year-old man with chronic, refractory schizophrenia was hospitalized because of his symptoms of hostility, aggression, insomnia, delusions, and auditory hallucinations, despite his medication with clozapine 200 mg per day. His initial laboratory studies revealed no remarkable findings. Clozapine was titrated to 350 mg per day for marked psychotic symptoms, but it seemed to be only slightly effective. Meanwhile, he complained of salivation worsening and wanted to discontinue clozapine treatment because of this adverse effect. We then added amisulpride 600 mg per day for augmentation of clozapine. Interestingly, there was a significant improvement in his auditory hallucinations, delusions, conceptual disorganization, and on the positive and negative syndrome scale (PANSS). Also, the adverse effect of sialorrhea was improved during the following days and nights.

Discussion

Clozapine is used to treat severe schizophrenia symptoms in people who have not responded to or only partially responded to other antipsychotics. Sialorrhea is a common side effect leading to treatment noncompliance, occurring in about 31%–54% of patients receiving clozapine therapy.1 Amisulpride, an atypical antipsychotic, possesses a higher selective binding to the D2/D3 dopamine receptor and a minimal effect on other receptors.2 Clozapine produces moderate blocking of the D2 dopamine receptors, whereas amisulpride is a potent antagonist of D2 dopamine receptors. The efficacy of the combination may be due to the complementary receptor profile of the two drugs. In this report, amisulpride might be augmentative therapy for clozapine in patients who are not responsive to or only partially responsive to clozapine. Kreinin et al.3 reported a significant reduction in hypersalivation with addition of amisulpride to ongoing clozapine therapy. In our case, both daytime as well as nocturnal sialorrhea improved after the addition of amisulpride. However, the definite underlying mechanism is still unknown. In summary, our case suggested that amisulpride improve the antipsychotic effect of clozapine while improving the major adverse event of sialorrhea. Amisulpride augmentation of clozapine might be an optional approach to treatment-refractory schizophrenia.

References

1.
Davydov L, Botts SR: Clozapine-induced hypersalivation. Ann Pharmacother 2000; 34:662–665
2.
Natesan S, Reckless GE, Barlow KB, et al.: Amisulpride: the “atypical” atypical antipsychotic: comparison to haloperidol, risperidone, and clozapine. Schizophr Res 2008; 105(1–3):224–235
3.
Kreinin A, Novitski D, Weizman A: Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. Int Clin Psychopharmacol 2006; 21:99–103

Information & Authors

Information

Published In

Go to The Journal of Neuropsychiatry and Clinical Neurosciences
Go to The Journal of Neuropsychiatry and Clinical Neurosciences
The Journal of Neuropsychiatry and Clinical Neurosciences
Pages: E15
PubMed: 21948906

History

Published online: 1 July 2011
Published in print: Summer 2011

Authors

Details

Hsiu-Wen Chiu, M.D.
Department of Psychiatry, Beitou Armed Forces Hospital, 60, Xinmin Rd., Beitou Dist., Taipei 112, Taiwan.
Yu-Chi Ku, M.D.
Department of Psychiatry, Beitou Armed Forces Hospital, 60, Xinmin Rd., Beitou Dist., Taipei 112, Taiwan.
Tien-Chun Li, M.D.
Department of Psychiatry, Beitou Armed Forces Hospital, 60, Xinmin Rd., Beitou Dist., Taipei 112, Taiwan.
Hsin-Te Huang, M.D.
Department of Psychiatry, Beitou Armed Forces Hospital, 60, Xinmin Rd., Beitou Dist., Taipei 112, Taiwan.

Notes

e-mail address: [email protected] (Ms. Chiu), [email protected] (Dr. Huang)

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share